Legal and labeling regulations concerning cosmetics and mail-order sales
First written in FY2020. 2 of 6 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2021: 2 of 11 companies on the "Worse" side.
15 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The Company is working to keep abreast of regulatory developments by strengthening its legal function and working with external specialists. It is implementing company-wide compliance training and establishing a rigorous review system for product labeling and advertising content.」
It continues to address the risks associated with legal regulations, including the Pharmaceutical and Medical Devices Act, Food Sanitation Act and Act against Unjustifiable Premiums and Misleading Representations, through its legal function, external specialists, training and reviews. - FY2023WorsenedAnnual report
「Under the Act against Unjustifiable Premiums and Misleading Representations, new stealth-marketing regulations were introduced effective 1 October of that year based on the designation under Cabinet Office Public Notice No. 19 dated 28 March 2023 (Reiwa 5).」
It describes a new regulatory environment in which stealth-marketing regulations were introduced effective 1 October 2023, in addition to the existing Pharmaceutical and Medical Devices Act and Act on Specified Commercial Transactions. Cooperation with lawyers and specialist consultants and employee training are also continuing. - FY2022-Q2MitigatedAnnual report
「The impact of advertising regulations, which constrained new-customer acquisition in the first quarter of the fiscal year, has gradually subsided.」
It states that the restrictions on new-customer acquisition caused by advertising regulations gradually eased during the second quarter. - FY2022-Q1MaterialisedAnnual report
「To respond to changes in the guidelines of relevant authorities following the amended Pharmaceuticals and Medical Devices Act, which took effect in August 2021, and the amended Specified Commercial Transactions Act, which was introduced in stages from July 2021 through 2024, we revised our internal regulations and reviewed our advertising language. This restricted communication with prospective customers and consequently reduced advertising investment required for new customer acquisition.」
Amendments to the Pharmaceutical and Medical Devices Act and the Act on Specified Commercial Transactions, as well as changes to guidelines, were implemented, resulting in revisions to advertising claims and restrictions on communication with prospective customers. - FY2021RestatedAnnual report
「To keep abreast of amendments to relevant laws and regulations and changes in the external environment, the Group seeks to raise awareness of legal compliance through consulting contracts with specialist consultants, participation in seminars hosted by those consultants and employee training.」
It continues to implement measures addressing regulations concerning cosmetics, direct-to-consumer sales and labeling. - FY2020First statedAnnual report
「The Company is subject to legal regulations including the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, the Act on Specified Commercial Transactions and the Act against Unjustifiable Premiums and Misleading Representations.」
It seeks to ensure compliance with laws and regulations through contracts with specialist consultants, participation in seminars and employee training.